Sanofi Launches Mid‑Stage Study on FSGS and MCD Treatments
For patients living with focal segmental glomerulosclerosis (FSGS) or minimal change disease (MCD), treatment options can feel frustratingly limited. But a new clinical study from Sanofi is testing three promising therapies that could change the game — and it's actively recruiting participants.
Here’s what you need to know about the study, why it matters, and how some patients may be able to enroll.
What is This Study About?
Sanofi has launched a Phase 2a clinical trial to explore whether three experimental drugs (frexalimab, SAR442970, and rilzabrutinib) can safely reduce protein loss in urine (proteinuria), a key marker of kidney damage in FSGS and MCD. These conditions damage the kidney’s filtering units, often leading to swelling, fatigue, and long-term complications.
Why it Matters
Current treatments like steroids or calcineurin inhibitors don’t work for everyone and often come with serious side effects. This new study could offer a safer, more targeted approach.
Each drug in the trial works by targeting specific immune pathways suspected of contributing to kidney damage.
Frexalimab blocks immune signals that may trigger cell injury in the kidneys. SAR442970 and rilzabrutinib target immune cells thought to harm the glomerular filter.
If these therapies reduce proteinuria and increase remission rates, it could lead to major breakthroughs in kidney care.
Who Can Join the Study?
The trial is currently recruiting patients aged 16 to 75 with confirmed primary FSGS or MCD. Only 80 participants will be enrolled, so time is a factor.
Participants will receive one of the three experimental treatments or a placebo for 24 weeks. The total study period is 76 weeks, including up to 18 doctor visits. All participants, doctors, and researchers are blinded to which treatment is given to ensure unbiased results.
What's in it For Patients?
While there’s no guarantee of benefit, participants could:- Gain early access to innovative treatments not yet on the market
- Help advance research that may lead to new options for the broader FSGS/MCD community
- Receive close medical monitoring throughout the study period
If one or more drugs prove safe and effective, they could advance to larger trials and eventually become available to more patients, especially those who haven’t responded well to existing therapies.
Want to Stay in the Loop?
We help patients stay informed about new treatments, clinical trials, and opportunities for enrollment, especially in rare and hard-to-treat kidney diseases like FSGS and MCD.
If you want early alerts about trials like this, help understanding eligibility, or access to expert insights before they’re widely shared, consider subscribing.
Sign up to claim your 1-month free trial and get immediate access to our latest dossier of treatment news, clinical trials, and emerging therapies.